Latest research on Octreotide

Octreotide is the acetate salt of a cyclic octapeptide. It is a long-acting octapeptide with pharmacologic properties mimicking those of the natural hormone somatostatin.

Octreotide interactions

For refractory thymoma and thymic carcinoma, the NCCN guidelines [12] recommend single-agent or non-platinum-based chemotherapy, such as Etoposide [25], Gemcitabine [26], Paclitaxel [27], Ifosfamide [28], Pemetrexed [29], 5-Fluorouracil (5-FU) and Leucovorin [30], and Octreotide (including long acting-formulation) plus Prednisolone [31]. [source, 2016]
Systemic chemotherapies for GEP-NET included Octreotide, VIP (vincristine, Ifosfamide, Cisplatin), XELOX (Capecitabine, Oxaliplatin), EP (Etoposide, Cisplatin), pazopanib, Sunitinib, everolimus, and XELIRI (Capecitabine, Irinotecan). [source, 2016]
The investigators in the NCIC Clinical Trials Group (CTG) MA.14 clinical trial ( Identifier: NCT00002864) randomized women, regardless of lymph node (LN) status, to Tamoxifen (TAM) with or without Octreotide LAR [15]. [source, 2016]
BCI had a strong prognostic effect on RFS in patients with early-stage breast cancer treated with Tamoxifen alone or with Tamoxifen and Octreotide. [source, 2016]
The combination of the symptoms, response to Octreotide and findings of the imaging studies prompted the decision to Perform an exploratory laparotomy. [source, 2016]
Oral potassium supplementation, Octreotide and oral Prednisolone were still required for symptom relief. [source, 2016]
Prednisone and Indomethacin are also considered to be effective in alleviating the clinical symptoms; therefore, Octreotide, at a dosage of 100 mg daily, combined with 20 mg Prednisone daily were administered to the patient in this study to control the symptom of diarrhea and arrest the liver metastasis. [source, 2016]
Somatostatin analogues improve hormone-mediated symptoms and reduce tumor volume; however, long-term application of Octreotide is likely to lead to drug resistance and inhibit the secretion of insulin, Growth hormone and Glucagon, which is problematic. [source, 2016]
Balancing severe GI bleeding and NSTEMI, Clopidogrel therapy was continued, Dalteparin sodium was replaced with Unfractionated heparin (UFH), and transfusion and Octreotide Acetate (Sandostatin®, Novartis International AG, Basel, Switzerland) treatment were included as part of the therapeutic approach. [source, 2016]
In this setting, blood transfusion, Omeprazole, and Octreotide prevented further bleeding. [source, 2016]